Top in endocrinology: New criteria for diagnosing obesity; Medicare price negotiations
A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, including measuring body fat to diagnose obesity instead of BMI alone.
The commission report also recommended that health care professionals conduct a further assessment to determine whether a person has clinical or preclinical diabetes after confirming that they have excess body fat.
“We hope the new reframing will increase the accuracy of diagnosis, and because of that, it will lead to a more personalized treatment of people with obesity, proportionate and appropriate to their individual needs,” Francesco Rubino, MD, chair of the commission and professor of metabolic and bariatric surgery at King’s College London, told Healio.
It was the top story in endocrinology last week.
In another top story, CMS announced 15 new drugs for the second cycle of Medicare Part D price negotiations that will go into effect in 2027.
Read these and more top stories in endocrinology below:
Lancet report offers a ‘new reframing’ for defining, diagnosing obesity
A new international commission report has proposed new criteria for diagnosing obesity that could dramatically change the way it is categorized and managed in the future. Read more.
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS. Read more.
GLP-1 receptor agonists tied to similar thyroid cancer risk as DPP-IV inhibitors
Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a DPP-IV inhibitor, according to findings published in Thyroid. Read more.
DKA concerns remain paramount in FDA’s denial of sotagliflozin for type 1 diabetes
For the second time since 2019, the oral SGLT1 and SGLT2 dual inhibitor sotagliflozin has been denied FDA approval for adults with type 1 diabetes, with elevated risk for diabetic ketoacidosis being a primary concern. Read more.
Zoledronate infusions every 5 years may lower fracture risk for early postmenopausal women
Early postmenopausal women who receive zoledronate every 5 years have a lower risk for morphometric vertebral fractures than those receiving placebo, according to trial findings published in The New England Journal of Medicine. Read more.